替比夫定阻断乙肝病毒母婴传播的有效性及安全性评价  

Evaluation on Effect and Safety of Tebivudine in Block Transmission of Mother-to-child Transmission of Hepatitis B Virus

作　　者：曲思麦 刘江福[2] 狄佳[1] 娄宪芝[1] QU Simai;LIU Jiangfu;DI Jia;LOU Xianzhi(Affiliated Central Hospital of Shenyang Medical College,Shenyang 110024,China)

机构地区：[1]沈阳医学院附属中心医院,辽宁沈阳110024 [2]福建医科大学附属泉州第一医院

出　　处：《中国医学创新》2020年第8期131-134,共4页Medical Innovation of China

基　　金：辽宁省自然科学基金(20170540882)。

摘　　要：目的:观察与分析替比夫定阻断乙肝病毒母婴传播的有效性及安全性。方法:选取2017年5月-2018年10月本院收治的160例HBsAg阳性孕妇为研究对象,根据治疗方案的不同分为对照组和试验组,各80例。对照组采用常规干预,试验组采用替比夫定+常规干预。比较两组孕妇治疗前及分娩前、分娩后4周、24周的HBV-DNA、ALT及CK-MB水平、不良妊娠发生率、剖宫产率及产后出血率,同时比较两组新生儿感染率、胎龄、体质量、身长、头围及Apgar评分。结果:分娩前和分娩后4、24周,试验组孕妇的HBV-DNA均低于对照组,新生儿感染率低于对照组(P<0.05)。两组ALT、CK-MB水平、不良妊娠发生率、剖宫产率及产后出血率比较,差异均无统计学意义(P>0.05);两组新生儿胎龄、体质量、身长、头围及Apgar评分比较,差异均无统计学意义(P>0.05)。结论:替比夫定阻断乙肝病毒母婴传播的有效性及安全性均较高,因此应用价值较高。Objective:To observe and analyze the effect and safety of Tebivudine in the block transmission of mother-to-child transmission of hepatitis B virus.Method:A total of 160 pregnant women with HBsAg-positive in our hospital from May 2017 to October 2018 were chosen as the study objects,and they were divided into the control group and the experience group,according to the treatment methods,80 cases in each group.Routine intervention was used in the control group and Tibivudine + routine intervention in the experimental group.Then the HBV-DNA,ALT and CK-MB levels before the treatment,before delivery,4 weeks and 24 weeks after delivery,incidence of adverse pregnancy,cesarean section rate and postpartum hemorrhage rate of pregnant women in two groups were compared,and the infection rate,gestational age,body weight,length,head circumference and Apgar score of newborns in two groups were compared.Result:The HBV-DNA of pregnant women in the experience group before delivery,4 weeks and 24 weeks after delivery were lower than those of the control group,the infection rate of newborns was lower than that of control group,there were statistically significant differences (P<0.05).The ALT and CK-MB levels,incidence of adverse pregnancy,cesarean section rate and postpartum hemorrhage rate of two groups were compared,there were no statistically significant differences (P>0.05),the gestational age,body weight,length,head circumference and Apgar score of newborns in two groups were compared,there were no statistically significant differences (P>0.05).Conclusion:The effect and safety of Tebivudine in the block transmission of mother-to-child transmission of hepatitis B virus is higher,so the application value is higher.

关 键 词：替比夫定 阻断乙肝病毒 母婴传播 有效性 安全性 

分 类 号：R714.251[医药卫生—妇产科学]